Febuxostat Versus Allopurinol on Hepatic Steatosis in MAFLD Patients

Inclusion Criteria: * Ages 18-65. * Males and Females * Metabolic syndrome according to the NCEP ATP III definition \[13\]: present of three or more of the following five criteria are met: * Waist circumference over 40 inches (men) or 35 inches (women), Central obesity - defined as waist circumference ≥ 102 cm for Men and ≥ 88 cm for women * Blood pressure over 130/85 mmHg, * Basting triglyceride (TG) level over 150 mg/dl, * Fasting high-density lipoprotein (HDL) cholesterol level less than 40 mg/dl (men) or 50 mg/dl (women), * Fasting blood sugar over 100 mg/dl. * Serum uric acid levels of \> 420μmol/L (\>7 mg/dL) in men and \>360 μmol/L (\>6 mg/dL) women. Exclusion Criteria: * Renal insufficiency defined by serum creatinine \> 2.0 mg/dl. * Patients with obvious abnormal liver function: serum transaminase (ALT, AST, one of them) exceed 2 times the upper limit of normal reference value. * Have a history of viral hepatitis, or serological examination suggests hepatitis virus infection, or have a history of other liver diseases. * Complementation with diabetes, or fasting blood glucose \>7.8mmol/L, or HbA1c \>7.5%. * Severe hypertension, blood pressure ≥ 160/100 mmHg. * A history of allergy to febuxostat and allopurinol; in the acute active phase of gout. * Drinking equivalent to alcohol intake ≥30g/d(male), ≥20g/d(female). * Complicated coronary heart disease. * Cardiac dysfunction (cardiac function grade 2 or above). * Patients with asthma and other respiratory diseases. * Intestinal diseases such as inflammatory bowel disease. * Any history of systemic malignancy in the past 5 years. * Use of uric-lowering drugs in the 4 weeks before screening: febuxostat, allopurinol, benzbromarone. * Morbid obesity (BMI\>37.5kg/m2). * Triglyceride ≥5.0 mmol/L was found to be significantly abnormal in baseline examination. * had received systemic hormone or immunosuppressive therapy within 3 months prior to screening or expected to receive hormone or immunosuppressive therapy in the future. * Use of other drugs affecting uric acid metabolism were adjusted within 4 weeks before screening: losartan, fenofibrate, irbesartan, thiazide diuretics, loop medullar diuretics, compound antihypertensive agents containing diuretics. Other drugs that may affect liver fat content were taken within 4 weeks before screening. * Women who are lactating or pregnant.